Adverse Drug Reactions, Drug Interactions and Pharmacovigilance

From Verify.Wiki
Jump to: navigation, search
Adverse Drug Reactions, Drug Interactions and Pharmacovigilance
Date May 07-11, 2018
Place Oxford, United Kingdom

The Adverse Drug Reactions, Drug Interactions and Pharmacovigilance course[1] is a one-week module of the MSc in Experimental Therapeutics. Offered by the Department of Oncology and the Department for Continuing Education’s CPD Centre, the teaching will be led by Dr Michael Theodorakis, Radcliffe Department of Medicine, University of Oxford, and will feature face-to-face lectures and tutorials from some of the country's leading clinicians and scientists. The module can be taken as a stand-alone short course. It includes group work, discussions, guest lectures, and interaction and feedback with tutors and lecturers. To quantify the importance of drug-drug interactions (DDIs) in the occurrence of adverse drug reactions (ADRs) reported with serotoninergic reuptake inhibitors in a pharmacovigilance database. All spontaneous reports of ADRs registered in 2008 by the Midi-Pyrénées PharmacoVigilance Centre that contained mention of one of the serotoninergic reuptake inhibitor (SRI) antidepressants marketed in France were reviewed.Around 40% of ADRs reported with SRIs were related to DDIs. Most of these occurred after association with psychotropics, antithrombotics, or diuretics, especially in the elderly. (Ref///


  • Safety of medicines for human use – principles and framework
  • Adverse drug reactions – mechanisms, analysis, reporting, vulnerable populations
  • Drug interactions – epidemiology, mechanisms, detection and prevention
  • Principles of optimal pharmacotherapy
  • Pharmacovigilance – principles, methodologies, risk management & pharmacoepidemiology
  • Clinical trials – bioethics of drug safety, pharmacovigilance in trial design, applications for marketing authorisation
  • Regulatory framework and legislation
Clinical trials allow the drug to be tested for safety by different ethnic population. Due to the higher medical needs and increasing disease prevalence, developing countries are becoming a hub for clinical trial execution. The clinical trials market has been estimated to reach USD 14.2 billion in 2016 and is projected to reach around USD 22 billion by the year 2021, and the annual growth rate of (7.5%). There are additionally numerous clinical trials started by scholarly clinical scientists. Whether started by industry or by scholastic clinical examiners and research is frequently performed in national, European and overall consortia, which can be expansive ones. Clinical research brings up moral and security issues. Clinical research is exceedingly controlled. To encourage and coordinated efforts crosswise over fringes. Cite error: Closing </ref> missing for <ref> tag

Verification history